Jinling Pharmaceutical Company: The branch received a notice of acceptance for Eralgoran tablets.

Jinling Pharmaceutical Industry announced that its subsidiary, Nanjing Jinling Pharmaceutical Factory, recently received a notification letter from the National Medical Products Administration for the acceptance of Elagolix tablets, with specifications of 150mg and 200mg. Elagolix is an oral gonadotropin-releasing hormone antagonist approved by the FDA on July 23, 2018, making it the first oral GnRH receptor antagonist approved specifically for the treatment of moderate to severe pain associated with endometriosis. The drug is currently listed in the national "Second Batch of Encouraged Generic Drug Catalog." If the clinical trials progress smoothly, it will enrich and enhance the company's product line layout and improve the company's product competitiveness.